Manage Your Liver
Q:

Why is the hepatitis C virus (HCV) so difficult to kill?

A:

The hepatitis C virus (HCV) infects millions of people worldwide. Patients are desperate for an effective treatment but medical professionals and the pharmaceutical industry have yet come up with the ideal one. There are two main reasons why HCV is so hard to kill.

 

First, HCV knocks out the host’s innate immunity. By constant mutation, HCV may be able to escape detection and elimination by the host’s immune system. [1] Therefore, it is almost impossible for the host to kill the virus without external help.

 

Second, HCV is highly mutable. HCV is an RNA virus and lacks proofreading ability as it replicates, therefore dozens of mutated forms arise. Even within an individual, slightly different genetic versions of HCV are present. According to WHO, there are at least 11 HCV genotypes identified throughout the world. The genotype is the strain of the virus to which patients were exposed when they were infected. [1]

 

The genotype generally does not affect the progression of liver diseases. However, it is of great clinical importance; different genotypes vary in their responsiveness to HCV treatments. For example, compared with genotype 1, patients with genotypes 2 and 3 are more likely to achieve a sustained virological response to interferon/ribavirin therapy. In addition, therapy duration also varies among different genotypes. Patients with genotypes 2 or 3 generally are treated with combination therapy for only 24 weeks, while patients with genotype 1 usually receive treatment for 48 weeks. [2]

 

Traditionally, combination therapy with interferon/ribavirin is recommended for HCV patients. Interferons do not directly kill the virus; instead they boost the immune system response to attack the virus. The success rate for such therapy is very low and often comes with unbearable side effects such as fever, headache and other flu-like symptoms. [3]

 

In recent years, new medications for HCV were developed. One of the most promising is Harvoni, a direct-acting antiviral (DAA) medication. Unlike interferon, DAAs directly inhibit the ability of HCV to replicate. Harvoni is a combination of two DAAs where one interferes with the reproduction of the virus’s genetic material, while the other interferes with a protein needed to complete the virus life cycle in the liver cell.

 

Although Harvoni claims to have high success rates in clinical studies, not many patients can afford it due to its extremely high cost. Moreover, a person could get infected again even after successful treatment. [4]

 

Despite the introduction of new drugs, treatment options for hepatitis C patients are still limited. If patients are unable to receive antiviral treatment due to genotype or financial reasons, or have tried and failed, they should shift their treatment focus to protecting liver function and reducing inflammation (ALT).

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
As many of you may have known, reports of the new hepatitis C treatment being associated with a higher risk of liver cancer were found when the treatment came out. One of the most notable cases is the development of a 7 cm cancer tumour in just 6 months after the patient receiving the new treatment. Researchers have been investigating on this issue, and a
A:
Ever since new treatments for hepatitis C have been released in the market, the curing rates have improved to a great extent, reaching more than 90 percent. However, patients often experience ongoing mental side effects after the treatments. According to an article published on Oxford Academic, 30%-80% of hepatitis C patients undergoing treatments experienced some forms of psychiatric side effects, with fatigue and depression affecting up to 80% and 50% of the patient population res
Hit Questions
A:
The liver carries out essential functions, including detoxifying harmful substances in your body, cleaning your blood and making new blood and other vital nutrients. Cirrhosis is scarring of the liver caused by long-term liver damage. The loss of liver cells turns into scar tissue which prevents the liver working normally, reducing or in some cases, completely losing liver function. Cirrhosis is a long-term chronic liver damage; it is often caused by chronic live
A:
ALT (Alanine Aminotransferase / SGPT) is a type of enzyme found in liver cells. When the liver cells are functioning normally, the ALT enzymes should be contained within the liver cells.    You can imagine each liver cells as a balloon, and the ALT enzymes are the air inside the balloon. When the balloon is damaged, the air will be released. And when the liver cells is damaged, ALT enzymes are released into the bloodstream, therefore we are able to find out the l
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us
Subscribe To Our Mailing List And
Never Miss Another Great Promotion!
Join our mailing list to receive latest new about our company, plus health articles. You will also be able to receive early bird discount from us!
Maybe Later, Thank you.
Subscribe success! You will receive latest new soon.